Form 4: Cytokinetics Director Lynne Parshall Executes Stock Option and Sells Shares
SEC Form 4
Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on June 3, 2024.
Summary
- On June 3, 2024, Lynne Parshall, a director of Cytokinetics Inc., executed a transaction involving the company's common stock.
- Parshall exercised a non-qualified stock option to acquire 5,000 shares of common stock at a price of $10.68 per share.
- Simultaneously, Parshall sold 5,000 shares of common stock at a price of $48.64 per share.
- Following these transactions, Parshall directly owns 15,600 shares of Cytokinetics Inc.
- Parshall also holds 15,000 non-qualified stock options.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
- The sale of shares could have a minor, temporary impact on the stock price.
Key Dates
| Date | Description |
|---|---|
| 06/17/2019 | Date the Non-Qualified Stock Option was exercisable |
| 05/14/2029 | Expiration date of the Non-Qualified Stock Option |
| 06/03/2024 | Date of transaction: exercise of stock options and sale of shares |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.